

Facts & Figures




16

state-of-the-art production facilities

in **14** countries, including all major pharma hubs

Global Footprint



€899 million sales

in fiscal 2023 (+9 %)

Compared to fiscal 2022

€239 million EBITDA

in fiscal 2023 (+9 %)



>1,000

patents and designs developed

~120

employees

active in R&D collaborating with an exclusive network of partners

On average, **more than 25,000 injections per minute** are provided to patients worldwide through a SCHOTT Pharma product.

~13

billion products delivered every year

Glass syringes



Polymer syringes



Cartridges



Vials



Ampoules




Broad ready-to-use portfolio

Market & Customers

>50 % of medicines approved

by the FDA in 2022 were injectables.¹

Growth of the **injectable drugs** market expected to outpace total Pharma drug market by **1.4x**.²



Estimated injectable drugs market size (€ bn)

The **top 30** global pharma companies use **SCHOTT Pharma's solutions**.

>1,800

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

Growth opportunities from structural trends

mRNA therapies

New drug categories require deep-cold storage (-100°C)



SCHOTT Pharma currently offers the only prefillable syringes for these applications³

GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

Homecare solutions

Enabling patients to inject drugs at home, reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers

Manufacturing transformation

Smaller patient populations require more flexible filling lines







SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility

¹Based on FDA.gov

²Based on GlobalData estimated data

³No competitor disclosed a product with mentioned specifications so far

ESG Responsibility



Executive Board

**Andreas Reisse,
CEO**

- 35 years of experience
- Heading SCHOTT's pharma business since 2010
- Previously headed SCHOTT's Tubing business unit
- Master Degree in Industrial Engineering

**Dr. Almuth Steinkühler,
CFO**

- 15 years of experience
- Leading the finance organization since 2022
- Previous management roles with thyssenkrupp and Continental
- PhD in Management Accounting

¹ Scope 1 & 2; Defined as corporate CO₂ footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)

SCHOTT Pharma's Governance

KGaA (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three **corporate bodies**:

- **general partner** (Komplementär)
- **supervisory board** (Aufsichtsrat)
- **general shareholders' meeting** (Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

Supervisory Board

Shareholder representatives



Chairman
Peter Goldschmidt,
CEO Stada AG



Deputy Chairman
Dr. Wolfgang Wienand,
CEO Siegfried Holding AG



Eva Kienle,
CFO
KWS Saat SE & Co. KGaA



Ann-Kristin Erkens,
CFO
SIG Group AG

Employee representatives



Mario Just,
SCHOTT Pharma



Christine Wening,
SCHOTT Pharma

Press contact

Joana Kornblum

joana.kornblum@schott.com

+49 (0) 151/29 22 35 52

Lea Kaiser

lea.kaiser@schott.com

+49 (0) 151/68 91 71 95